Sunday, April 28, 2019

Hansa Biopharma Interim Report January-March 2019

MALMÖ, Sweden, April 29, 2019 /PRNewswire/ -- January – March 2019 Highlights The European Medicines Agency (EMA) accepted Hansa's Marketing Authorization Application (MAA) for review of IDEFIRIX (imlifidase). This acceptance marks the beginning of the regulatory review process for...



from PR Newswire: https://prn.to/2PzM2nT

No comments:

Post a Comment